The skeleton: Endocrine regulator of phosphate homeostasis

  title={The skeleton: Endocrine regulator of phosphate homeostasis},
  author={M{\'a}ire E. Doyle and Suzanne Jan de Beur},
  journal={Current Osteoporosis Reports},
Phosphorus is an essential element in skeletal development, bone mineralization, membrane composition, nucleotide structure, and cellular signaling. Phosphate, the principal form in which phosphorus is found in the body, is regulated by the complex interplay of the hormones parathyroid hormone (PTH), calcitriol (1,25[OH]2 vitamin D3), and fibroblast growth factor 23 (FGF23). These collectively govern bone mineralization, absorption of phosphorus by the intestine, and renal tubular reabsorption… 

Bone tissue as a systemic endocrine regulator.

Bone morphogenetic protein (BMP) has also been found to have anabolic effects on the skeleton by activating bone formation during embryonic development, as well as in the postnatal period of life.

Dietary Phytase and Lactic Acid-Treated Cereal Grains Differently Affected Calcium and Phosphorus Homeostasis from Intestinal Uptake to Systemic Metabolism in a Pig Model

High intestinal availability of dietary phosphorus (P) may impair calcium homeostasis and bone integrity in growing pigs and alter homeostatic regulatory mechanisms as indicated by serum Ca, P, vitamin D, and fibroblast growth factor 23 levels.

Vitamin D metabolism, functions and needs: from science to health claims

Vitamin D, through food fortification and supplementation, is a promising new health strategy and thus provides opportunities for food industry and nutrition researchers to work together towards determining how to achieve this potential health benefit.

Magnesium Phosphate Bioceramics for Bone Tissue Engineering

The synthesis methods, mechanical properties, in’vitro and in vivo biocompatibility of MgP bioceramics are discussed and the recent developments in metal ion‐doped MgPs and M gP scaffolds for bone tissue engineering are highlighted.

Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

The American Academy of Oral and Maxillofacial Surgeons has provided detailed recommendations for the management of bisphosphonate-related ONJ, which are suggested to be applied in themanagement of patients with exposure to denosumab, bevacizumab and sunitinib.

Clinical factors associated with severe hypophosphataemia after kidney transplant

This analysis demonstrates an association between variables relating to better graft function and hypophosphataemia, and the links with biochemical measures of mineral-bone disease remain less clear.

Multiscale poroelastic modeling of bone

La pose d’une Prothese Totale de Hanche est l’une des chirurgies orthopediques les plus pratiquees, et represente un enjeu economique et de sante publique majeur. Ainsi, il est essentiel de

Lameness in fattening pigs – Mycoplasma hyosynoviae, osteochondropathy and reduced dietary phosphorus level as three influencing factors: a case report

The presented case of severe lameness in fattening pigs revealed that three different influences presumably act in pathogenesis, and clinical symptoms disappeared after some changes in diet composition and anti-inflammatory treatment of individual animals.

Diet and DNA damage in infants: the DADHI study



Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Evidence is presented that FGF23 is a physiological regulator of serum phosphate and 1,25-dihydroxyvitamin D (1,25[OH]2D) by generating FGF 23-null mice, indicating that F GF23 is essential for normal phosphate and vitamin D metabolism.

The parathyroid is a target organ for FGF23 in rats.

It is shown that FGF23 acts directly on the parathyroid through the MAPK pathway to decrease serum PTH, which adds a new dimension to the understanding of mineral homeostasis.

Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

FGF23 works, at at least in part, in a VDR-independent manner, and FGF23 production is also regulated by multiple mechanisms involving V DR-independent pathways.

Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.

Novel findings provide evidence that FGF-23 directly regulates renal 1alpha-hydroxylase gene expression via activation of the ERK1/2 signaling pathway.

Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo*

There was a feedback loop existing among serum phosphorus, 1α,25(OH)2D3, and FGF-23, in which the novel phosphate-regulating bone-kidney axis integrated with the parathyroid hormone-vitamin D3 axis in regulating phosphate homeostasis.

The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23.

This review will focus upon recently discovered factors that are overexpressed in tumors associated with tumor-induced osteomalacia and have reported activity consistent with effecting Pi balance in vivo.

FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.

The results suggest that FGF-23 is involved in the pathogenesis of these three hypophosphatemic disorders and directly link PHEX and F GF-23 within the same biochemical pathway.

Inhibition of Intestinal Sodium‐dependent Inorganic Phosphate Transport by Fibroblast Growth Factor 23

  • K. MiyamotoMikiko ItoM. KuwahataS. KatoH. Segawa
  • Biology
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2005
The present study suggests that FGF23(R179Q) reduces intestinal sodium‐dependent Pi transport activity and type IIb NaPi protein levels by a mechanism that is dependent on VDR.